AGC to acquire Malgrat Pharma Chemicals SLU of Spain

AGC Inc., a global leader in the manufacture of glass, chemicals and high-tech materials, has announced an agreement with Boehringer Ingelheim to acquire Malgrat Pharma Chemicals SLU ("MPC"). MPC is a subsidiary of Boehringer Ingelheim, which manufactures synthetic pharmaceutical active ingredients (* 1) for the group. With the acquisition of MPC, AGC will have its first FDA registered site in Europe in the field of synthetic pharmaceutical CDMOs (* 2).

The transaction remains subject to the approval of the relevant antitrust authorities and compliance with the closing conditions under the share purchase agreement.

MPC has extensive experience in manufacturing cGMP (* 3) marketed synthetic pharmaceuticals as well as compounds in clinical development at different scales. Leveraging AGC's fluoridation technologies, extensive in-house drug discovery experience and the CDMO business developed in Japan, AGC, with the addition of MPC, will be able to offer its CDMO services from an expanded asset base, meeting the needs of European customers and expanding its presence in the European market.

AGC Group's AGC plus management policy identifies life sciences as one of its strategic activities. AGC will continue to actively invest in this area to provide globally unified, high quality services to both synthetic and biopharmaceutical customers. In addition, by maximizing the synergies of each site, the technical capabilities of the group will be strengthened, which will better contribute to pharmaceutical companies, patients and society in general.

0 Comments Write your comment

    1. Loading...